Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Quince Therapeutics relaunched as IRulya Therapeutics, effective immediately, and its stock will trade on Nasdaq under the new symbol IRLA starting October 12, 2026. The rebrand follows the May 2026 merger with Orphai Therapeutics and a ~$115 million private placement; the company holds $116 million in cash, expected to fund operations through the end of 2028. Leadership was overhauled: Brigette Roberts, M.D. is the new CEO, with a new CFO and COO, while former Quince CEO Dirk Thye and COO Brendan Hannah resigned; four new directors joined the board.
Key figures
- Cash runway
- through the end of 2028
- Cash balance
- $116 million
- Private placement gross proceeds
- $115 million
- Shares outstanding post conversion
- 10841470
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.